Ansh Enterprises

Borviz 2 mg Injection belongs to a group of anti-cancer medicines used to treat adult patients with multiple myeloma and mantle cell lymphoma who have received at least one prior therapy. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer it affects several areas of the body, such as the spine, skull, pelvis, and ribs. Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL). It develops when B-cells (also called B-lymphocytes) become abnormal. B-cells are white blood cells that fight infection.

Borviz 2 mg Injection contains 'Bortezomibx' that works by interfering with how proteasomes work, which may cause cancer cells to die and may stop cancer from growing and eventually kills them.

Borviz 2.5 Injection is used in the treatment of multiple myeloma and mantle-cell lymphoma. It shows its working by stopping or slowing down the growth of cancer cells.

Borviz 2.5 Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Bortecad 2.5 Injection is used in the treatment of multiple myeloma and mantle-cell lymphoma. It shows its working by stopping or slowing down the growth of cancer cells.

Bortecad 2 Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Bortenat 2mg Injection is used in the treatment of multiple myeloma and mantle-cell lymphoma.

Bortenat 3.5mg Injection is used in the treatment of multiple myeloma and mantle-cell lymphoma. It shows its working by stopping or slowing down the growth of cancer cells.

Bortenat 3.5mg Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Fatigue, nausea, vomiting, and loss of appetite are some common side effects of this medicine. You may be advised to drink plenty of fluids every day during the treatment. You should not drive or operate machinery as medicine may cause tiredness and dizziness. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.

BortiRel (Bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) or subcutaneous use (SC). Bortezomib is a modified dipeptidyl boronic acid. Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins.

BortiRel (bortezomib) for Injection is a proteasome inhibitor indicated for Multiple Myeloma part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation and for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already underg